PAS
JANX icon

Point72 Asia (Singapore)’s Janux Therapeutics JANX Stock Holding History

Point72 Asia (Singapore)’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-70
Closed -$3.75K – 1045
2024
Q4 		$3.75K Buy
+70
New +$3.7K ﹤0.01% 801

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Point72 Asia (Singapore)'s JANX Position: Q1 2025 in Review

Point72 Asia (Singapore) sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 70 shares — an estimated $3.75K sold.

Point72 Asia (Singapore) first reported a position in JANX in Q4 2024 and held it in 1 quarter. The position peaked at $3.75K in Q4 2024. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

  • Point72 Asia (Singapore) reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 70 Janux Therapeutics shares in Q1 2025, an estimated $3.75K.
  • Point72 Asia (Singapore) first reported a position in Janux Therapeutics in Q4 2024 and held it in 1 quarter.
  • Point72 Asia (Singapore)'s Janux Therapeutics position peaked at $3.75K in Q4 2024.
  • 181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q1 2025, filed 15 May 2025.